Rinascimento 2: SPN-817 Fase 2, in doppio cieco, studio controllato con placebo su adulti con convulsioni a insorgenza focale
Rinascimento 2: uno studio in doppio cieco, randomizzato, controllato con placebo, multicentrico, a group parallelo per valutare l'efficacia, la sicurezza e la tollerabilità di SPN-817 negli adulti con convulsioni di insorgenza focale
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 administered as an adjunctive treatment in adults with focal onset seizures that have previously failed at least 2 anti-seizure medication (ASM) regimens. Participants will be taking 1 to 4 ASMs, with at least 4 seizures during the 6-week Screening Period. Following the Screening Period, eligible participants will be randomized 2:1 to SPN-817 (3.0-4.0 mg BID) or placebo and begin the Titration Period (8-10 weeks). In both treatment groups, open-label ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic adverse events [AEs]) will be taken (8 mg oral [PO]) prophylactically approximately 30 minutes before each study medication (SM) dose (ie, BID) during the Titration Period as an antiemetic. After the target dose of 3.0-4.0 mg BID is reached, participants will enter the Maintenance Period (14 weeks). Ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic AEs) may be taken as needed as either a preventative or therapeutic antiemetic during the Maintenance Period. Participants who complete the Maintenance Period will have the opportunity to enroll in a separate open-label study for continued treatment with SPN-817. Participants who do not enroll in the open-label study will undergo a Tapering Period (up to 4 weeks) and a follow-up safety phone call.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Navid Saeidi, MS
- Numero di telefono: 240-403-5328
- Email: nsaeidi@supernus.com
Backup dei contatti dello studio
- Nome: Supernus Clinical Trials
- Numero di telefono: 240-403-5838
- Email: clinicaltrials@supernus.com
Luoghi di studio
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Reclutamento
- Royal Brisbane and Women's Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Reclutamento
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Reclutamento
- Monash Medical Centre
-
Fitzroy, Victoria, Australia, 3065
- Reclutamento
- St. Vincent's Hospital Melbourne
-
Melbourne, Victoria, Australia, 3004
- Reclutamento
- The Alfred Hospital
-
Parkville, Victoria, Australia, 3052
- Reclutamento
- Royal Melbourne Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Reclutamento
- The Perron Institute for Neurological and Translational Science
-
-
-
-
-
Blagoevgrad, Bulgaria, 2700
- Reclutamento
- Multiprofile Hospital for Active Treatment PULS
-
Pleven, Bulgaria, 5809
- Reclutamento
- Medical Center (MC) Academica
-
Rousse, Bulgaria, 7012
- Reclutamento
- Medical Center - Teodora EOOD
-
Sofia, Bulgaria, 1113
- Reclutamento
- Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "Sveti Naum" EAD
-
-
Sofia-Grad
-
Sofia, Sofia-Grad, Bulgaria, 1431
- Reclutamento
- University Multiprofile Hospital for Active Treatment Aleksandrovska, Clinic for Neurology Diseases
-
-
-
-
-
Lublin, Polonia, 20-064
- Reclutamento
- NZOZ NEUROMED M. and M. Nastaj Spółka Partnerska
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polonia, 30-727
- Reclutamento
- Pratia MCM Kraków
-
-
Maloplski
-
Krakow, Maloplski, Polonia, 30-363
- Reclutamento
- Centrum Medyczne Plejady
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polonia, 01-684
- Reclutamento
- Centrum Medyczne NeuroProtect
-
Warsaw, Masovian Voivodeship, Polonia, 02-172
- Reclutamento
- TZ Clinical Research powered by Pratia
-
Warsaw, Masovian Voivodeship, Polonia, 02-952
- Reclutamento
- Neurosphera
-
-
Pomeranian Voivodeship
-
Gdynia, Pomeranian Voivodeship, Polonia, 81-537
- Reclutamento
- Synexus Polska Sp. z o. o. Oddział w Gdyni
-
Sopot, Pomeranian Voivodeship, Polonia, 81-735
- Sospeso
- Terra Centrum Leczenia
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polonia, 40-123
- Reclutamento
- NZOZ Wielospacjalistyczna Poradnia Lekarska Synapsis
-
Katowice, Silesian Voivodeship, Polonia, 40-650
- Reclutamento
- Novo-Med Zieliński i Wsp. Sp.J.
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85004
- Reclutamento
- Xenoscience
-
Phoenix, Arizona, Stati Uniti, 85006
- Reclutamento
- Banner University Medical Center-Phoenix
-
Tucson, Arizona, Stati Uniti, 85724
- Reclutamento
- University of Arizona College of Medicine - Tucson
-
Tucson, Arizona, Stati Uniti, 85718
- Reclutamento
- Center for Neurosciences
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- Reclutamento
- Clinical Trials, Inc
-
-
California
-
Los Angeles, California, Stati Uniti, 90048
- Reclutamento
- Clinical Research Institute
-
Mission Hills, California, Stati Uniti, 91345
- Reclutamento
- Access Community Clinical Trials
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- University of California, Irvine
-
West Hills, California, Stati Uniti, 91307
- Reclutamento
- Focus Clinical Research
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06510
- Reclutamento
- Yale University
-
-
Florida
-
Gulf Breeze, Florida, Stati Uniti, 32561
- Reclutamento
- Northwest Florida Clinical Research Group, LLC
-
Kissimmee, Florida, Stati Uniti, 34744
- Reclutamento
- Ilumina Medical Research
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami
-
Miami, Florida, Stati Uniti, 33133
- Reclutamento
- Visionary Investigators Network
-
Orlando, Florida, Stati Uniti, 32806
- Terminato
- Research Institute of Orlando, LLC
-
Port Charlotte, Florida, Stati Uniti, 33952
- Reclutamento
- Medsol Clinical Research Center
-
Contatto:
- Maria Vasconcelos, RN
- Numero di telefono: 941-623-9744
- Email: mvasconcelos@medsolcrc.com
-
Port Saint Lucie, Florida, Stati Uniti, 34990
- Reclutamento
- Cleveland Clinic Florida Martin Health
-
-
Illinois
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Southern Illinois University School of Medicine
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40223
- Reclutamento
- University of Louisville Physicians
-
-
Louisiana
-
Covington, Louisiana, Stati Uniti, 70433
- Reclutamento
- Neurocare of Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70121
- Sospeso
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins University
-
Bethesda, Maryland, Stati Uniti, 20817
- Reclutamento
- Mid Atlantic Epilepsy and Sleep Center
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Reclutamento
- Wayne State University - Detroit Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Reclutamento
- Northeast Regional Epilepsy Group - Hackensack
-
Neptune City, New Jersey, Stati Uniti, 07753
- Reclutamento
- Hackensack Meridian Health Jersey Shore University Medical Center
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Reclutamento
- Albany Medical Center
-
Amherst, New York, Stati Uniti, 14226
- Reclutamento
- Dent Neurologic Institute
-
New York, New York, Stati Uniti, 10021
- Reclutamento
- Northwell Health - Lenox Hill
-
Rochester, New York, Stati Uniti, 14618
- Reclutamento
- University of Rochester Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Stati Uniti, 28806
- Reclutamento
- Asheville Neurology Specialists
-
Charlotte, North Carolina, Stati Uniti, 28211
- Reclutamento
- OnSite Clinical Solutions, LLC
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Reclutamento
- Neurology Institute Epilepsy Center of Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Reclutamento
- Thomas Jefferson University
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University Medical Center
-
-
Texas
-
El Paso, Texas, Stati Uniti, 79912
- Reclutamento
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research
-
Frisco, Texas, Stati Uniti, 75034
- Reclutamento
- Stryde Research
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- UT Health Houston
-
-
Virginia
-
McLean, Virginia, Stati Uniti, 22101
- Reclutamento
- Medstar Health Research Institute
-
-
-
-
-
Budapest, Ungheria, 1125
- Reclutamento
- Flash Clinic
-
Budapest, Ungheria, 1145
- Reclutamento
- SE, Idegsebeszeti es Neurointervencios Klinika, Epilepszia Centrum
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy Study Consortium, Inc (ESCI);
- Failed to achieve sustained seizure freedom after ≥2 tolerated, appropriately chosen, and adequately dosed ASM drug schedules;
- Able to keep accurate Seizure electronic diaries [eDiaries] (with the aid of a caregiver as needed);
- Has a body mass index (BMI) between 18.0 and 40.0 kg/m2;
- Treatment with a stable dose of 1 to 4 current ASMs for ≥28 days prior to screening. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to Visit 1. The diet plan should be maintained throughout the duration of the study;
- At least 4 clinically observable focal onset seizures accepted by the ESCI prior to the first dose of SM (during the days of baseline Seizure electronic diary [eDiary] data collection) and no more than a consecutive 21-day period that was free of these seizures. To be eligible for the study, participants must comply with the eDiary on at least 80% of the days of baseline data collection;
Exclusion Criteria:
- Has taken huperzine A within the past 6 months;
- Prior diagnosis of combined focal and generalized epilepsy syndrome as evidenced by severe developmental delay and multiple seizure types and confirmed by electroencephalography (EEG) (eg, Lennox-Gastaut syndrome). Participants should also be excluded in case of nondiagnostic information;
- History of or current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures;
- Only has seizures that are difficult to count; for example, seizures that are not clinically observable;
- History of uncountable seizures, such as seizures that happen in a cluster that are too rapid to be counted individually;
- History of status epilepticus within 6 months prior to screening;
- Vagus nerve stimulation, deep brain stimulation, responsive neurostimulator system, or other neurostimulation for epilepsy device implanted or activated within 1 year prior to screening; or epilepsy surgery within 1 year prior to screening. Stimulation parameters for devices must have been stable for at least 3 months prior to Screening. Battery change for any epilepsy devices will be allowed; however, stimulation parameters must remain stable during the duration of the study;
- Any suicidal behavior or suicidal ideation related to item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS assessment in the 1 year before screening; a suicide attempt in the last 2 years before screening; or more than 1 lifetime suicide attempt;
- Chronic concomitant therapy with non-ASMs that have potent cholinergic (central or peripheral) or potent central (only) anticholinergic pharmacology.
- History of >2 allergic reactions to an ASM or 1 serious hypersensitivity reaction to an ASM;
- Any other reason which, in the opinion of the Investigator, would prevent the participant from taking part in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: SPN-817
SPN-817, bid |
SPN-817 starting at 0.25 mg bid up to 4.00 mg bid |
|
Comparatore placebo: Placebo
Placebo, bid |
Placebo, bid |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period
Lasso di tempo: Baseline and Maintenance Period (Maintenance Week 1-14)
|
Percent change in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline |
Baseline and Maintenance Period (Maintenance Week 1-14)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Lasso di tempo: Baseline and Maintenance Period (Maintenance Week 1-14)
|
Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline. |
Baseline and Maintenance Period (Maintenance Week 1-14)
|
|
PCH from baseline in focal onset seizure frequency per 28 days over the entire Treatment Period
Lasso di tempo: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
Percent change in 28-day frequency of focal seizures during the entire Treatment Period (Titration Period + Maintenance Period) relative to baseline |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Lasso di tempo: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the Treatment Period (Titration Period + Maintenance Period) relative to baseline. |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Longest seizure-free interval over the entire Treatment Period
Lasso di tempo: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
The longest intervals in days between two seizures during the entire Treatment Period. |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Incidence of treatment-emergent adverse events (TEAEs)
Lasso di tempo: Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4
|
The percent of subjects who took at least one dose of SPN-817 and reported at least one adverse event during SPN-817 treatment. |
Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Maciej Gasior, MD, PhD, Supernus Pharmaceuticals, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 817P203
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .